Search company, investor...

Predict your next investment

PharmaCyte Biotech company logo
Corporation
HEALTHCARE | Drug Development
pharmacyte.com

Partners & Customers

10

About PharmaCyte Biotech

PharmaCyte Biotech is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as "Cell-in-a-Box."

Headquarters Location

23046 Avenida de la Carlota, Suite 600

Laguna Hills, California, 92653,

United States

917-595-2850

Want to inform investors similar to PharmaCyte Biotech about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest PharmaCyte Biotech News

PharmaCyte Biotech : Certificate of Incorporation/Bylaws - Form 8-K

Sep 7, 2023

N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Common Stock, Par Value $0.0001 Per Share PMCB The NasdaqStock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. As disclosed below, at the special meeting of PharmaCyte Biotech, Inc. (the "Company") held on August 31, 2023 (the "Special Meeting"), the Company's stockholders approved an amendment (the "Amendment") to the Company's Articles of Incorporation, as amended (the "Charter"), to increase the total number of authorized shares of the Company's common stock from 133,333,334 to 200,000,000. On September 6, 2023, the Company filed the Amendment with the Secretary of State of the State of Nevada with immediate effect. The summary of the Amendment contained herein does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, a copy of which is attached as Exhibit 3.1 hereto and incorporated herein by reference. Item 5.07 Submission of Matters to a Vote of Security Holders. On August 31, 2023, the Company held the Special Meeting via live webcast. At the Special Meeting, 11,422,363 shares of common stock, or approximately 68.01% of the outstanding shares of common stock entitled to vote, were represented by proxy or in person, representing a quorum. At the Special Meeting, the stockholders of the Company voted as set forth below on two proposals, each of which is described in detail in the Company's definitive proxy statement filed with the Securities and Exchange Commission on July 31, 2023. The final voting results for each matter submitted to a vote of the Company's stockholders are as follows: Proposal 1. Authorization of the Issuance of Shares. The authorization, for purposes of complying with Nasdaq Listing Rule 5635(d), of the issuance of shares of the Company's common stock underlying shares of convertible preferred stock and warrants issued by the Company pursuant to the terms of that certain Securities Purchase Agreement, dated May 9, 2023, by and between the Company and the investors named therein, in an amount equal to or in excess of 20% of the Company's common stock outstanding before the issuance of such convertible preferred stock and warrants (including any amortization payments made to the holders of convertible preferred stock in the form of issuance of shares of common stock and upon the operation of anti-dilution provisions contained in such convertible preferred stock and warrants): For

PharmaCyte Biotech Acquisitions

2 Acquisitions

PharmaCyte Biotech acquired 2 companies. Their latest acquisition was Bio Blue Bird on July 18, 2013.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

7/18/2013

$99M

Acquired

1

6/6/2011

Subscribe to see more

$99M

Subscribe to see more

0

Date

7/18/2013

6/6/2011

Investment Stage

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

Note

Acquired

Subscribe to see more

Sources

1

0

PharmaCyte Biotech Partners & Customers

10 Partners and customers

PharmaCyte Biotech has 10 strategic partners and customers. PharmaCyte Biotech recently partnered with The Board on August 8, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

8/15/2022

Partner

Peru

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

PharmaCyte Biotech said on Monday that it had signed a cooperation agreement with Iroquois Master Fund and its affiliates to includes two of Iroquois ' director designees to its Board of Directors .

1

1/1/2021

Partner

Singapore

Live Cell Encapsulation Market to Reach USD 313.13 Million by 2032, Driven by Growing Demand for Regenerative Medicine

By leveraging Merck KGaA 's expertise in drug development and Artios Pharma 's specialization in DNA damage response , the partnership aims to create novel therapies for cancer patients .

1

7/29/2020

Licensor

Hong Kong

PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests - PharmaCyte Biotech

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte Biotech , Inc. , including statements regarding the viability of the technology that is the subject to the Hai Kang Agreement , our ability to gain the necessary approvals to market and commercialize products under that Agreement , and the timing and commencement of our planned Phase 2b clinical trial in LAPC , which is subject to IND approval .

1

4/8/2020

Licensor

Hong Kong

Subscribe to see more

Subscribe to see more

10

7/22/2019

Licensor

Australia

Subscribe to see more

Subscribe to see more

10

Date

8/15/2022

1/1/2021

7/29/2020

4/8/2020

7/22/2019

Type

Partner

Partner

Licensor

Licensor

Licensor

Business Partner

Country

Peru

Singapore

Hong Kong

Hong Kong

Australia

News Snippet

PharmaCyte Biotech reaches agreement with Iroquois to include 2 board of directors

PharmaCyte Biotech said on Monday that it had signed a cooperation agreement with Iroquois Master Fund and its affiliates to includes two of Iroquois ' director designees to its Board of Directors .

Live Cell Encapsulation Market to Reach USD 313.13 Million by 2032, Driven by Growing Demand for Regenerative Medicine

By leveraging Merck KGaA 's expertise in drug development and Artios Pharma 's specialization in DNA damage response , the partnership aims to create novel therapies for cancer patients .

PharmaCyte Biotech Receives CE Mark for Licensed COVID-19 Molecular Tests - PharmaCyte Biotech

This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that express the current beliefs and expectations of the management of PharmaCyte Biotech , Inc. , including statements regarding the viability of the technology that is the subject to the Hai Kang Agreement , our ability to gain the necessary approvals to market and commercialize products under that Agreement , and the timing and commencement of our planned Phase 2b clinical trial in LAPC , which is subject to IND approval .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Join a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.